Drug Patent Watch
MARCH 12, 2025
The Unseen Heroes of Generic Drugs: Stability Testing 101 As a consumer, have you ever stopped to think about the rigorous process that goes into bringing a generic version of your favorite medication to market? For generic drug manufacturers, stability testing is a critical step in the development process.
Drug Patent Watch
MARCH 10, 2025
The Future of Generic Drugs: How Technology is Revolutionizing the Industry As we continue to navigate the ever-changing landscape of healthcare, one thing is clear: technology is playing an increasingly important role in shaping the future of generic drug development. The answer is yes and it's happening now.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
DECEMBER 10, 2024
Generic drug development is a complex process that involves not only scientific and medical expertise but also adherence to strict legal and ethical standards. Scientific expertise plays a crucial role in ensuring that generic drugs are held to the same standards of quality, safety, and efficacy as their brand-name counterparts.
Drug Patent Watch
DECEMBER 9, 2024
Scientists in this field analyze the chemical compounds in plants, animals, and microorganisms to discover potential new drugs. “Pharmacognosy is the bridge between traditional medicine and modern pharmaceutical science, offering a treasure trove of potential new drugs waiting to be discovered.”
pharmaphorum
OCTOBER 12, 2021
A data-mining study conducted by researchers in the US has found that an already-approved diuretic drug could have potential as a treatment for some patients with Alzheimer’s disease.
pharmaphorum
JUNE 4, 2021
While an increase in the number of prescriptions had been predicted because of the pandemic, the scientists said it was the sharp rise in antidepressant prescription costs which was a potential cause for concern. Shortage-related price concessions data published last May indicated the price of sertraline was up 823% to £14.32
Camargo
OCTOBER 14, 2021
These Q&A are intended to proactively respond to those scientific and regulatory topics that appear frequently in controlled correspondence addressed by OPQ, thereby allowing industry to move forward with certain generic drug development activities without the need to submit controlled correspondence to FDA.”. Ryan Key, PhD.
Expert insights. Personalized for you.
97 
Let's personalize your content